CA2961607C - Mk2 inhibitors and uses thereof - Google Patents

Mk2 inhibitors and uses thereof Download PDF

Info

Publication number
CA2961607C
CA2961607C CA2961607A CA2961607A CA2961607C CA 2961607 C CA2961607 C CA 2961607C CA 2961607 A CA2961607 A CA 2961607A CA 2961607 A CA2961607 A CA 2961607A CA 2961607 C CA2961607 C CA 2961607C
Authority
CA
Canada
Prior art keywords
compound
disorder
disease
aliphatic
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2961607A
Other languages
English (en)
French (fr)
Other versions
CA2961607A1 (en
Inventor
Matthew David Alexander
Claudio Chuaqui
John MALONA
Joseph John MCDONALD
Yike Ni
Deqiang Niu
Russell C. Petter
Juswinder Singh
Chittari Pabba
Guobin MIAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Celgene CAR LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene CAR LLC filed Critical Celgene CAR LLC
Publication of CA2961607A1 publication Critical patent/CA2961607A1/en
Application granted granted Critical
Publication of CA2961607C publication Critical patent/CA2961607C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2961607A 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof Active CA2961607C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
CA2961607A1 CA2961607A1 (en) 2016-03-24
CA2961607C true CA2961607C (en) 2023-03-28

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2961607A Active CA2961607C (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Country Status (30)

Country Link
US (5) US9458175B2 (https=)
EP (2) EP3912981A1 (https=)
JP (3) JP6556225B2 (https=)
KR (1) KR102457848B1 (https=)
CN (1) CN106998692B (https=)
AU (1) AU2015317741B2 (https=)
BR (1) BR112017005266B1 (https=)
CA (1) CA2961607C (https=)
CL (1) CL2017000576A1 (https=)
CO (1) CO2017003279A2 (https=)
CY (1) CY1124215T1 (https=)
DK (1) DK3193611T3 (https=)
EA (1) EA037299B1 (https=)
EC (1) ECSP17023281A (https=)
ES (1) ES2874561T3 (https=)
HR (1) HRP20210529T1 (https=)
HU (1) HUE054347T2 (https=)
IL (1) IL251051B (https=)
LT (1) LT3193611T (https=)
MA (1) MA40534B1 (https=)
MX (2) MX373341B (https=)
PL (1) PL3193611T3 (https=)
PT (1) PT3193611T (https=)
RS (1) RS62017B1 (https=)
SA (1) SA517381115B1 (https=)
SG (2) SG11201701861RA (https=)
SI (1) SI3193611T1 (https=)
SM (1) SMT202100311T1 (https=)
TW (1) TWI744217B (https=)
WO (1) WO2016044463A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
US11098057B2 (en) * 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170200A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
EP3596085A4 (en) * 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
WO2020072580A1 (en) * 2018-10-02 2020-04-09 Disc Medicine, Inc. Matriptase 2 inhibitors and uses thereof
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20220154094A (ko) * 2020-02-14 2022-11-21 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ulk1/2 억제제를 이용한 단일 및 병용 요법
KR20220153582A (ko) 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 마크로시클릭 ulk1/2 억제제
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
KR20230044446A (ko) * 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
JP2023550347A (ja) * 2020-11-12 2023-12-01 アクティーヴァ セラピューティクス， インコーポレイテッド 血管漏出障害および内皮バリア障害を処置することにおける使用のためのｍｋ２活性化化合物
CN116670142A (zh) * 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
EP4608401A2 (en) * 2022-10-27 2025-09-03 Bristol-Myers Squibb Company Mk2 inhibitors and uses thereof
JP2026505836A (ja) * 2023-02-07 2026-02-18 セルジーン コーポレーション Ｍｋ２キナーゼ分解剤として有用である化合物および組成物
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN121368484A (zh) * 2023-06-26 2026-01-20 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
JP4734346B2 (ja) 2005-02-04 2011-07-27 セノミックス インコーポレイテッド 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX2009014247A (es) 2007-07-16 2010-01-28 Novartis Ag Compuestos heterociclicos utiles como inhibidores de mk2.
AU2008317057B8 (en) 2007-10-22 2014-02-13 Merck Sharp & Dohme Corp. Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN104136576B (zh) 2012-02-22 2020-10-16 默克专利股份有限公司 液晶介质
WO2013146963A1 (ja) * 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
WO2014011902A1 (en) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EA201590644A1 (ru) * 2012-09-24 2015-09-30 Клермонт Спиде Способ и система с управляемыми мобильным отправителем доступом к данным и удалением данных
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
WO2016032882A1 (en) 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
EP3242886A4 (en) 2015-01-08 2018-08-29 Moerae Matrix, Inc., Formulation of mk2 inhibitor peptides
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법

Also Published As

Publication number Publication date
US20160075720A1 (en) 2016-03-17
KR102457848B1 (ko) 2022-10-25
CO2017003279A2 (es) 2017-09-29
MA40534A (fr) 2016-03-24
EP3193611A2 (en) 2017-07-26
MX373341B (es) 2020-05-26
JP6556225B2 (ja) 2019-08-07
PL3193611T3 (pl) 2021-10-04
EP3193611B1 (en) 2021-03-24
RS62017B1 (sr) 2021-07-30
BR112017005266B1 (pt) 2022-11-01
EA037299B1 (ru) 2021-03-05
EP3193611A4 (en) 2018-02-28
CL2017000576A1 (es) 2017-12-01
MA40534B1 (fr) 2021-04-30
IL251051A0 (en) 2017-04-30
KR20170063734A (ko) 2017-06-08
CN106998692A (zh) 2017-08-01
EA201790380A1 (ru) 2017-08-31
IL251051B (en) 2019-11-28
US11584757B2 (en) 2023-02-21
CN106998692B (zh) 2020-09-08
CY1124215T1 (el) 2022-05-27
EP3912981A1 (en) 2021-11-24
TWI744217B (zh) 2021-11-01
US20170114073A1 (en) 2017-04-27
ECSP17023281A (es) 2017-06-30
WO2016044463A2 (en) 2016-03-24
CA2961607A1 (en) 2016-03-24
HUE054347T2 (hu) 2021-08-30
US9458175B2 (en) 2016-10-04
HRP20210529T1 (hr) 2021-08-06
DK3193611T3 (da) 2021-05-10
SI3193611T1 (sl) 2021-08-31
US10577380B2 (en) 2020-03-03
JP2022078315A (ja) 2022-05-24
SA517381115B1 (ar) 2021-03-09
US20210053984A1 (en) 2021-02-25
JP2019194236A (ja) 2019-11-07
US10253040B1 (en) 2019-04-09
MX2020005213A (es) 2020-08-20
WO2016044463A3 (en) 2016-09-01
US20190375762A1 (en) 2019-12-12
AU2015317741A1 (en) 2017-04-20
BR112017005266A2 (pt) 2017-12-12
US9790235B2 (en) 2017-10-17
JP7375072B2 (ja) 2023-11-07
TW201617351A (zh) 2016-05-16
NZ730603A (en) 2024-02-23
SG10201902326XA (en) 2019-04-29
SMT202100311T1 (it) 2021-07-12
PT3193611T (pt) 2021-05-28
ES2874561T3 (es) 2021-11-05
JP2017529367A (ja) 2017-10-05
SG11201701861RA (en) 2017-04-27
AU2015317741B2 (en) 2020-01-16
LT3193611T (lt) 2021-08-25
MX2017003359A (es) 2017-11-22

Similar Documents

Publication Publication Date Title
CA2961607C (en) Mk2 inhibitors and uses thereof
EP3080103B9 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CN112638910B (zh) 新的杂环胺衍生物及包含其的药物组合物
WO2016090079A1 (en) Heteroaryl compounds and uses thereof
EP4209485A1 (en) Compound having antitumor activity and use thereof
KR20210108433A (ko) 티에노피리디논 화합물
HK1241225A1 (en) Mk2 inhibitors and uses thereof
HK1241225B (en) Mk2 inhibitors and uses thereof
CN120676947A (zh) 可用作mk2激酶降解剂的化合物和组合物
WO2024092115A2 (en) Mk2 inhibitors and uses thereof
HK40058075A (en) Intermediates and processes for the preparation of biaryl compounds
HK1229333B (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
HK1229333A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200828